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Abstract 
Coronavirus disease 2019 (COVID‐19) is caused by severe acute respiratory syndrome coronavirus‐2. The clinical presentation 
of this virus mainly manifests in the respiratory system but may also lead to severe complications in the cardiovascular system. 
The global burden of COVID‐19 has led to an unprecedented need to gain further insight into patient outcomes, management, 
and clinical practice. This review aims to provide an overview of the current literature on heart failure (HF) hospitalizations, 
management, and care pathways for supporting patients during and beyond this pandemic. A literature review of five areas 
of interest was conducted and included: (i) HF hospitalization; (ii) recognizing the needs and supporting HF patients during 
COVID‐19; (iii) supporting rehabilitation services; (iv) transitioning to a telehealth framework; and (v) the need for evidence. 
Patients with new‐onset or existing HF are particularly vulnerable, but a significant reduction in HF hospital admissions has 
been reported. During these periods of uncertainty, the current care pathways for acute and elective cardiac patients have 
had to change with the relocation of HF services to protect the vulnerable and reduce transmission of COVID‐19. Optimizing 
community HF services has the potential to reduce the pressures on secondary care during the recovery from this pandemic. 
Telemedicine and virtual health care are emerging technologies and overcome the risk of in‐person exposure. Successful 
remote delivery of cardiac rehabilitation services has been reported during the pandemic. Delivery of a robust telehealth 
framework for HF patients will improve communication between clinician and patient. The reduction in HF admissions is a 
concern for the future and may result in unintended mortality. New‐onset and current HF patients must understand their 
diagnosis and future prognosis and seek help and support using the appropriate platform when needed. Realigning HF services 
and the use of telemedicine and virtual health care has great potential but needs to be carefully understood to ensure 
engagement and approval in this population to overcome barriers and challenges. 
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Introduction caused by severe acute respiratory syndrome coronavirus‐2 
(SARS‐CoV‐2).2,3 Its clinical presentation mainly affects the re-
The global spread of the novel coronavirus disease 2019 spiratory system but also has severe consequences on other 
(COVID‐19) has been unprecedented since it first emerged organ systems, for example, the cardiovascular and metabolic 
in Wuhan, Hubei Province, China, in December 2019.1 One systems, resulting in multiple organ failure.4–6 The global bur-
of the deadliest pandemics in modern history, COVID‐19 is den of COVID‐19 has resulted in 23 918 447 confirmed cases 
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and 819 945 deaths (as of 26 August 2020).7 COVID‐19 may 
only cause mild or even no symptoms,8 but typical indicators 
at hospital admission include fever, shortness of breath, 
coughing, fatigue, and dyspnoea.9,10 The global population 
is susceptible to this virus, but advancing age, being male, se-
vere obesity, pre‐existing co‐morbidities, and underlying car-
diovascular disease including heart failure (HF) have a poorer 
prognosis.9,11–18 
Patients who are elderly with multiple co‐morbidities (both 
cardiovascular disease and diabetes) are more susceptible to 
left ventricular hypertrophy, diastolic dysfunction, and HF, 
which makes them vulnerable to higher pulmonary vascular 
pressures.19 New‐onset or worsening HF is a common compli-
cation in patients with COVID‐19,20–23 with documented poor 
survival rates of ~60%.22 Furthermore, nearly 50% of patients 
who die from COVID‐19 with a diagnosis of HF have no previ-
ous history of either hypertension or cardiovascular disease.24 
A review of the symptom burden of COVID‐19 highlighted that 
dyspnoea is the most prominent symptom, but the primary 
cause of death is by respiratory failure or HF or both.25 In a 
large observational study, nearly three‐quarters of patients di-
agnosed with COVID‐19 had at least one pre‐existing condi-
tion, and over half were hypertensive.26 In end‐stage HF 
patients, myocardial injury has resulted from COVID‐19,27 
but the pathophysiological mechanisms between the virus, 
cardiac injury, and HF are not yet understood.28 At present, 
we are unable to determine the long‐term effects of 
COVID‐19 on the cardiovascular system and can only rely on 
the SARS‐CoV virus outcomes as an indicator.29 However, de-
terioration in myocardial function has been reported in the 
short term with findings suggesting that patients who recently 
recovered from COVID‐19 presented with lower left and right 
ventricular ejection fraction, higher left ventricular 
end‐diastolic volume, and raised native T1 and T2 values vs. 
both healthy controls and risk factor‐matched controls.30 
Besides, the prognosis of COVID‐19 patients is worse in 
those with existing conditions such as cardiovascular 
disease.30 Individuals who are older and have existing cardiac 
co‐morbidities have higher mortality from COVID‐19 than 
non‐cardiac patients.31 COVID‐19‐induced myocardial injury, 
confirmed with higher troponin concentration on admission 
to hospital, is more likely in those who have a history of cor-
onary artery disease, atrial fibrillation, and HF.2 COVID‐19‐
positive patients admitted with both reduced left ventricular 
ejection fraction or impaired right ventricular function and 
tricuspid regurgitation > 1 are more likely to have a poorer 
prognosis than those with normal cardiac function.28 In a 
case report, acute respiratory distress syndrome in a patient 
with COVID‐19 was found to mimic HF with reduced ejection 
fraction.32 
A larger proportion of angiotensin‐converting enzyme‐2 
(ACE2)‐positive cells in cardiomyocytes, and a greater expres-
sion of ACE2 found in HF patients, is associated with greater 
risk of mortality in comparison with those without underlying 
medical conditions.33 It has been hypothesized that hyperten-
sive patients treated with angiotensin‐converting enzyme in-
hibitors (ACEIs) and angiotensin receptor blockers (ARBs) are 
at increased risk of developing COVID‐19 and potentially 
worse outcomes.34 The European Society of Cardiology and 
other cardiology societies encourage treatment with renin– 
angiotensin system antagonists in patients with cardiovascu-
lar disease given the inconclusive data on the association be-
tween the up‐regulation of systemic or tissue ACE2 and risk 
of COVID‐19.35 A large retrospective cohort study of COVID‐
19‐positive patients found no association with mortality 
when comparing prior users of ACEIs or ARBs with non‐
users.36 Tomasoni et al. reviewed both the harmful and 
protective effects of ACEI/ARB treatment but suggested that 
their use ‘may counteract increased angiotensin II AT1 
receptors stimulation favoured by the loss of the 
counter‐regulatory effects of the downregulated ACE2’.1 Al-
though underlying cardiovascular disease increases the risk 
of a poorer prognosis from COVID‐19 and patients with these 
conditions are more likely to be prescribed with ACEIs or 
ARBs, the evidence suggests that the use of these medica-
tions does not increase the risk of COVID‐19.37 Indeed, prior 
use of ACE inhibitors, ARBs, beta‐blockers, calcium channel 
blockers, or thiazide diuretics showed no association with a 
higher risk of testing positive for COVID‐19.38 
Primary care practice has changed dramatically as a result 
of COVID‐19 with the transition to telephone and video con-
sultations, which are reported as more efficient than stan-
dard consultations, thereby conserving time.39 Video calls 
are also being utilized for practice meetings with staff in pri-
mary care.39 For HF patients, the usual patterns of care have 
changed during this pandemic, with the majority of practice 
converting to telehealth with reduced in‐person outpatient 
visits.40 Guidance on the continuation of clinical trials during 
and after COVID‐19 has provided alternative methods for 
measurement of endpoints and highlighted that practicing 
physicians and researchers have an obligation even during 
these difficult times to continue to improve patient out-
comes, management, and clinical practice.41 New communi-
cation methods that are being advised between clinical care 
teams, researchers, and patients such as telehealth, remote 
assessments, and in‐person procedures have been delayed.42 
This article provides an overview of the current literature 
on HF hospitalizations, management, and care pathways for 
supporting patients during and beyond COVID‐19. 
Heart failure hospitalization 
In London, admission rates for acute HF have been signifi-
cantly lower during the peak of the pandemic vs. the same 
period in 2019.43 Likewise, in Italy, a 49% decrease in acute 
HF admissions was recorded from February to April 2020 
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compared with the same period in 2019.44 A similar trend has 
been reported in Denmark with significantly lower rates of 
new‐onset HF diagnoses and hospital admissions for worsen-
ing HF during the lockdown period of 2020 vs. the same pe-
riod in 2019.45 In Germany, emergency admissions for HF 
declined by 22% between March and April 2020 vs. the same 
period in 2019.46 Likewise, the USA has reported a similar de-
cline in HF hospitalizations.47,48 Despite lower admissions 
rates, when patients do present, they are at a more critical 
stage of the disease progression with higher New York Heart 
Association (NYHA) class III or IV at admission (96% vs. 77%) 
and more severe peripheral oedema (39% vs. 14%) in 2020 
compared with 2019.43 However, no differences in HF sever-
ity, admission to intensive care unit, length of stay, or mortal-
ity have been reported elsewhere between the pre‐COVID‐19 
and COVID‐19 periods.48 During the COVID‐19 period, HF 
clinic volume has been reported as one‐half less vs. the same 
period in 2019, and the authors suggest that those with more 
stable HF will likely have deferred their clinic appointment 
during this period.49 
It should not be underestimated that there will be a ‘tidal 
wave’ effect shortly owing to HF patients avoiding urgent 
care during the pandemic.50 This will impact on health care 
services and potentially result in unintended mortality from 
HF.50 A potential ‘weathering the storm’ mentality may be 
present in patients owing to fears of contamination in hospi-
tals and a realignment of care pathways for HF treatment and 
management.47 More advanced or severe complications in 
cardiac conditions are currently presenting43 and may pres-
ent further post‐pandemic, which may lead to a rise in mor-
bidity and mortality.51 Delayed care or reluctance of 
patients to seek medical attention earlier may result in valve 
disease progressing to symptoms of advanced or decompen-
sated HF.52 
Barghash and Pinney53 highlighted possible reasons for the 
dramatic decline in HF hospitalizations, which include reduced 
dietary indiscretions due to restaurant closures, improve-
ments in medication adherence, virtual follow‐up care pro-
vided, reduction in daily energy expenditure, and refusal to 
attend hospital for worsening symptoms owing to fears of ex-
posure to the virus. In contrast, social isolation during the pan-
demic may result in HF destabilizations and adverse events 
due to changes in dietary habits such as processed food and 
lifestyle behaviours (decreased physical activity levels)54 as 
well as quarantine‐induced stress resulting in depression, so-
cial isolation, and behavioural addiction disorders.55 
To improve patient access and confidence in attending 
care facilities, it has been demonstrated that relocating HF 
services to isolated areas of admission or peripheral specialty 
units has prevented transmission of COVID‐19 in advanced HF 
and cardiac transplantation patients and needs to be consid-
ered more widely to protect and promote outpatient visits.56 
For example, colour‐coded zones have been implemented in 
an HF unit in Milan, Italy, to ensure isolation of infected, 
suspected, and no‐symptom patients.57 However, the 
authors recognize that the zone system was implemented 
to maximize the lack of personal protective equipment 
(PPE) and to save time between patients.57 
Recognizing the needs and supporting 
heart failure patients during 
coronavirus disease 2019 
The current care pathways for acute and elective cardiac pa-
tients have changed dramatically during this pandemic.5 
There is a need to protect patients from exposure to this virus 
during these periods of uncertainty.58 During the first wave of 
the pandemic, the highest risk patients were prioritized for 
review, but now, we are at the recovery phase, and both 
high‐risk and intermediate‐risk patient care need initiation 
to minimize disease progression.59 Optimizing community 
HF services during the recovery from the pandemic has the 
potential to reduce the pressures on secondary care.59 Based 
on our literature‐guided insights, strategies for improved HF 
management during and after the COVID‐19 pandemic is de-
scribed in Table 1. New‐onset and current HF patients must 
understand their diagnosis and future prognosis. Prior to 
COVID‐19, the majority of patients did not understand their 
diagnosis, and the meaning of the term ‘heart failure’60 and 
prognosis discussions have not been a regular feature in the 
management of HF.61 Communication between clinician and 
patient is evolving, and the recommendation is a transition 
to telehealth, remote monitoring, and virtual health care 
strategies.62 The British Society for Heart Failure recommends 
facilitating telephone or video consultations as the first 
method of communication with the patient from those who 
have suspected HF at the primary care referral stage, recently 
discharged acute HF, and known HF patients.63 By adopting 
virtual visits, patients have been given access to a platform 
to seek medical advice and avoid in‐person exposure, which 
is essential for HF patients.64 However, these new methods 
will have barriers and challenges such as patient access to 
the internet, the reluctance of the patient to adopt new tech-
nology, feeling self‐conscious on a video call, and the clini-
cian’s inability to perform a full physical examination.64 
Supporting rehabilitation services 
Successful remote delivery of cardiac rehabilitation services 
has been reported in Belgium during the pandemic with on-
line videos, website resources, and emails utilized, which 
highlights a potential future for cardiac telerehabilitation.65 
Future‐proofing cardiac rehabilitation services to telehealth 
have been provided by Thomas et al. with a transition to 
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Table 1 Strategies for improved heart failure management during and after the coronavirus disease 2019 pandemic 
Patient education at the time of diagnosis HF education needs to be addressed and the development of an 
online platform that is user‐friendly for all 
Prognosis assessment Information giving regarding prognosis should become a regular 
feature at the time of diagnosis and future assessments 
Risk assessment High‐risk and intermediate‐risk patients require optimization of 
treatment and minimize disease progression 
Redesigning cardiac rehabilitation services Optimizing and transitioning to telehealth. Reduce future hospital 
admission 
Abbreviation: HF, heart failure. 
phone management techniques (i.e. for setting goals, advice, 
and counselling), monitoring and reviewing patients by email, 
use of mHealth to personalize goals, videoconferencing, and 
utilizing web resources.66 Virtual cardiac rehabilitation guid-
ance has been published in Canada and highlights challenges 
with using this method such as loss of in‐person interactions 
as well as difficulties with risk stratification.67 The evidence 
suggests that exercise‐based cardiac rehabilitation has nu-
merous health benefits by significantly reducing the risk of 
reinfarction, cardiac, and cardiovascular mortality as well as 
all‐cause mortality.68 Redesigned services such as cardiac re-
habilitation are needed to ensure that HF patients can receive 
optimal treatment during and in the recovery from the 
pandemic,55 which may be beneficial in reducing the poten-
tial ‘tidal wave’ in admissions post‐pandemic. 
Transitioning to a telehealth 
framework 
On reflection, a pre‐existing robust telehealth framework for 
HF patients would have made remote clinical monitoring and 
early detection of decompensation easier during the 
pandemic.69,70 This is undoubtedly a recommended compo-
nent of future HF services to improve communication and 
support between the clinician and patient.69,70 We are now 
reacting to the pandemic rather than preparing, so the imple-
mentation and delivery of a telehealth system need to be 
supported by the clinician to provide an inclusive service to 
the patient.71 This is key now more than ever, especially with 
HF patients, to ensure that home‐based delivery is easy and 
intuitive.71 Health care professionals should be prepared for 
future virus outbreaks by becoming efficient and utilizing re-
mote and virtual technology with HF patients.59 The current 
use of PPE makes a person‐centred approach between clini-
cian and patient difficult, but reassurance and verbal encour-
agement from the clinician are vital.72 Resources and toolkits 
for health care professionals to guide palliative and end‐of‐
life care options for HF patients are emerging.59,72 
Interestingly, in Italy, Salzano et al. described the success-
ful implementation of a telemedicine service (using phone 
technology) for HF patients, which was provided throughout 
lockdown with 58% of patients accessing the service.73 
Remote cardiac care can detect underlying disease progres-
sion and prevent decompensation during this pandemic as 
demonstrated by colleagues using V‐LAP™ System in an NYHA 
class III patient.74 Successful adoption of a 
telemedicine‐based strategy has been integrated into an HF 
clinic during COVID‐19 with a transition to telemedicine ser-
vices from in‐person visits.49 However, the authors highlight 
the invaluable role of in‐person services and assessments, 
which should be recommended to the patient if needed.49 
The European Society of Cardiology75 HF guidelines pro-
mote the use of telephone and remote monitoring in the 
management and follow‐up of HF patients. Home monitoring 
of HF patients with non‐invasive and/or implantable devices 
is being adopted and has the capacity to transmit haemody-
namic data to the clinician, which allows for assessment and 
guides HF management, thereby reducing in‐person visits.76 
Remote titration strategies using telemonitoring have been 
effective in HF patients and resulted in reduced clinic visits, 
decreased time to dose optimization, and a greater number 
of patients achieving target doses (vs. standard titration).77 
Standardizing HF telemedicine is essential, and there is po-
tential to improve patient care and reduce costs to health 
care services.78 
The need for evidence 
Editors clearly have an obligation to support and disseminate 
the latest findings from COVID‐19, but the need for random-
ized controlled clinical trials, larger cohort studies (>100 pa-
tients), case reports, and design papers have been 
highlighted in the HF population.79 The publication of proto-
cols such as the BRACE CORONA Trial will be of interest.80 
Clinical trials for HF are currently restricted during this pan-
demic, and telehealth methods have been introduced for 
follow‐up to reduce the risk of missing data.81 Systematic lit-
erature reviews provide readers and cardiologists with the 
latest communication on COVID‐19 and cardiovascular 
complications.82,83 Researchers have to adapt to different 
ways of working with reduced opportunities in cardiovascular 
research for data collection, networking, presenting, and 
funding with strategic opportunities for online options 
needed.84 
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Conclusions Conflict of interest 
The need to gain information about the effect of COVID‐19 
on HF presentation and management is ever more present. 
The reduction in hospitalizations for HF is a concern, and 
the potential ‘tidal wave’ in admissions may result in more 
severe or advanced cases of HF in the near future. There 
is still a need to shield the most vulnerable, and future 
outbreaks may occur. Lessons should have been learnt from 
the current pandemic to provide better support for HF 
patients and optimize clinical services. More research is 
needed to ensure telehealth is acceptable and sustainable 
in this population now and during the recovery from the 
pandemic. 
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